Keratoconus, a common inherited ocular disorder resulting in progressive corneal thinning, is the leading indication for corneal transplantation in the developed world. Genome-wide association studies have identified common SNPs 100 kb upstream of ZNF469 strongly associated with corneal thickness. Homozygous mutations in ZNF469 and PR domain-containing protein 5 (PRDM5) genes result in brittle cornea syndrome (BCS) Types 1 and 2, respectively. BCS is an autosomal recessive generalized connective tissue disorder associated with extreme corneal thinning and a high risk of corneal rupture. Some individuals with heterozygous PRDM5 mutations demonstrate a carrier ocular phenotype, which includes a mildly reduced corneal thickness, keratoconus and blue sclera. We hypothesized that heterozygous variants in PRDM5 and ZNF469 predispose to the development of isolated keratoconus. We found a significant enrichment of potentially pathologic heterozygous alleles in ZNF469 associated with the development of keratoconus (P 5 0.00102) resulting in a relative risk of 12.0. This enrichment of rare potentially pathogenic alleles in ZNF469 in 12.5% of keratoconus patients represents a significant mutational load and highlights ZNF469 as the most significant genetic factor responsible for keratoconus identified to date.
INTRODUCTION
Keratoconus (MIM 148300), a common bilateral, progressive corneal thinning disorder (1) , is the leading indication for corneal transplantation in the developed world, accounting for 25% of the 2500 corneal transplants performed annually in the UK and a similar proportion of the 32 000 grafts performed annually in the USA (2) . Keratoconus usually arises in the teenage years and presents a significant health burden in work-age adults. The minimum incidence is 1 in 2000, but it is much more common in some ethnic groups (1, 3) . There is strong evidence for a heritable component in the development of keratoconus (4, 5) . Most studies describe autosomal dominant † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors. ‡ These authors contributed equally. * To whom correspondence should be addressed at: Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, Faculty of Health and Life Sciences, University of Liverpool, 3rd floor, UCD Building, Daulby Street, Liverpool L69 3GA, UK. Tel: +44 1517064070; Email: c.willoughby@ liverpool.ac.uk inheritance, with incomplete penetrance or variable expressivity (4) . However, in a genetic modelling study in a multi-ethnicity population a major recessive genetic defect was the most parsimonious (6) , although no recessive loci for keratoconus have been described to date.
The progressive corneal thinning associated with keratoconus [mean central corneal thickness (CCT) 450 -500 mm] (7) results in myopia and irregular corneal astigmatism. In healthy humans, CCT is a normally distributed quantitative trait with a mean of 536 + 31 mm (8), which has an estimated heritability up to 95% (9) . Genome-wide association studies (GWAS) in the healthy European and Asian populations have identified CCT-associated loci, with common SNPs upstream of zinc finger 469 (ZNF469 [MIM 612078]) the most strongly associated with CCT (10) (11) (12) (13) (14) . Mutations in three genes (ZNF469, COL5A1 and COL8A2) close or within these identified loci are responsible for rare Mendelian conditions that affect the corneal structure: brittle corneal syndrome, Ehlers -Danlos syndrome and posterior polymorphous corneal dystrophy, respectively (10) (11) (12) .
Brittle cornea syndrome (BCS) is an autosomal recessive generalized connective tissue disorder associated with extreme corneal thinning (220 -450 mm) and a high risk of corneal rupture (15, 16 (15) . In one family with BCS2, there was a relationship between the severity and age of onset of keratoconus and PRDM5 mutational status. Family members with a homozygous PRDM5 mutation (deletion of exons 9 -14) developed early and severe keratoconus, whereas one heterozygous family member developed keratoconus which was clinically milder with a later onset (15) . The relationship between the degree of CCT reduction and the presence of homozygous or heterozygous mutations in PRDM5 suggested a dosage effect (15) . Although none of the CCT-associated loci have been mapped to PRDM5, a common SNP (rs10518367) which is 70 kb upstream of PRDM5 has been associated with CCT in the European population at the significance level of P ¼ 8.9 × 10 25 . Given that rare ZNF469 and PRDM5 homozygous mutations result in the extreme corneal thinning disorder (BCS), and that there was evidence of a carrier ocular phenotype (keratoconus and corneal thinning) in some individuals with PRDM5 heterozygous mutations, and that common SNPs 100 kb upstream of ZNF469 are strongly associated with CCT, we undertook Sanger sequencing of both genes in patients with isolated keratoconus; a common ocular disease characterized by progressive corneal thinning and ectasia.
RESULTS
Heterozygous PRDM5 mutations in carrier individuals from BCS2 families can result in keratoconus (15) , and so the entire coding region and intron-exon junctions of PRDM5 (exons 1 -16) were sequenced in an initial 96 unrelated European patients with keratoconus. This analysis failed to identify any pathogenic variants, although eight known SNPs were detected (rs146268537, rs74320998, rs343192, rs17051264, rs34666716, rs12499000, rs75893420 and rs55774575). We therefore proceeded to Sanger sequence ZNF469 in the original cohort increased with additional keratoconus cases (total number of cases ¼ 112) of unrelated European patients with keratoconus from three study centres (Belfast, Leeds and Lausanne). Sequence variants detected by Sanger sequencing were classified as potentially pathogenic alleles by filtering using (i) ethnically matched population-specific control data from 784 individuals (outlined in the Materials and Methods); (ii) the data from dbSNP (Build 137), the May 2012 release of the 1000 Genomes (1KG) Project and the Exome Variant Server (EVS), NHLBI Exome Sequencing Project (ESP), with no allele having a minor allele frequency (MAF) .0.1% and (iii) classified as damaging using the Sorting Intolerant from Tolerant (SIFT) programme as outlined in the Materials and Methods and Figure 2 .
From these stringently filtered sequencing data, 12 potentially pathogenic non-synonymous heterozygous alleles were detected in the keratoconus cohort (Table 1 ) and two in-frame deletions: c.2904_2909delGTCGGG; p.Ser969_Gly970del and c.9011_ 9025delTTCCCGGGAACACCC; p.Leu3004_Thr3008del. In the keratoconus cohort following filtering, there remained 15 nonsynonymous classified as tolerated by SIFT which were absent from control data and had an MAF ,0.1% (Table 2 ). On the basis of poor conservation, six of these variants were classified as polymorphisms leaving nine variants of unknown significance. We detected 34 non-synonymous and 33 synonymous variants that were observed in both cases and controls, had an MAF ≥0.1% or were common variants, and were deemed nonpathogenic (Supplementary Material, Table S1 ). Overall, this study identified 34 novel variants (29 non-synonymous and 5 synonymous) that have been submitted to the NCBI dbSNP (Supplementary Material, Table S2 ). The severity of keratoconus was graded using the Amsler-Krumeich classification (18, 19) , and 10 individuals had grade Stage III or above indicating severe disease (illustrated in Fig. 1 ). Stages III and IV usually require surgical approaches for visual rehabilitation, and three individuals required corneal transplantation.
As there was the possibility that the alleles identified in the keratoconus subjects represented chance events, we Sanger sequenced the complete coding sequence of ZNF469 (13 203 bp) in 96 unaffected and unrelated European control samples (192 chromosomes) using the same experimental stringency as the case sequencing, and detected one non-synonymous heterozygous allele (c.1701G . T; p.Gln567His) deemed potentially pathogenic given our filtering criteria (Table 1) . There was a statistically significant enrichment of potentially pathogenic ZNF469 alleles in the keratoconus subjects (14 variants) compared with the 96 European controls (one variant); P ¼ 0.00102 [odds ratio (OR) 13.6, relative risk (RR) 12.0]. The allele frequency differences make it impossible for the rare ZNF469 alleles to be in linkage disequilibrium with the common variant signal that is within a 53 kb linkage disequi librium block 117 kb away from the 5 ′ end of ZNF46, and this has been replicated in diverse ancestries groups. The common variant, although strongly associated with corneal thickness, is not strongly associated with keratoconus (27) , associated with keratoconus susceptibility, but neither study reported genome-wide significant association. The identification of alleles that are predicted to be potentially pathogenic in 12.5% of keratoconus patients (14/ 112) makes ZNF469 the most significant genetic factor responsible for keratoconus identified to date. The small sizes of unrelated keratoconus case cohorts favour a candidate genes approach so that while the P-value obtained for evidence of a burden of ZNF469 rare damaging variants in the keratoconus cases is statistically significant, it would not have been in a genome-wide context. BCS is a rare recessive connective tissue disorder associated with consanguinity, with most BCS patients originating from countries in the Middle East and North Africa (16) . ZNF469, the gene for BCS1, was originally mapped to chromosome 16q24 in a single large Palestinian family and a homozygous frameshift mutation, (c.9527delG) predicted to result in a premature termination codon (p.Gln3178ArgfsX23), was subsequently reported (17) . Five further homozygous ZNF469 mutations have been reported in the literature: a founder mutation in five Tunisian patients (c.5934delA) predicted to result in a pre-mature termination codon (p.Gly1983AlafsX16), p.Gln1392X (Syrian origin) (28), p.Phe717SerfsX14 (15), p.Gln1757X (15) and one homozygous missense mutation (p.Cys3339Tyr) in a consanguineous Norwegian family (29) . Homozygous mutations in PRDM5 result in BCS2, and in some families PRDM5 heterozygous gene carriers display an ocular carrier state that includes a mildly reduced CCT (480 -505 mm), keratoconus and blue sclera (15) . Families harbouring homozygous and heterozygous PRDM5 mutations show a gene dosage relationship in terms of the degree of CCT reduction and the severity and age of onset of keratoconus (15) . There is no data available of CCT measurement or corneal topography for heterozygous carriers of ZNF469 mutations in BCS1 families. Our data for ZNF469 in the keratoconus population mirrors that seen in the ocular phenotype of PRDM5 heterozygous If predicted to be tolerated using SIFT the conservation of the residue was assessed and if poorly conserved the variant was classified as a polymorphism carriers. Heterozygous ZNF469 pathological alleles result in progressive corneal thinning and ectasia producing the keratoconus phenotype. The majority of potentially pathogenic alleles in the keratoconus cohort were missense variants likely to have a less deleterious effect on protein function than the ZNF469 truncating mutations commonly associated with BCS1. This further supports a gene dosage phenomenon wherein homozygous, severely deleterious ZNF469 mutations result in an early-onset severe and visually devastating ocular phenotype (extreme corneal thinning, ectasia and spontaneous rupture) (15), whereas heterozygous, missense ZNF469 mutations result in corneal thinning, ectasia and keratoconus. Further functional studies and cell-based assays are required to interrogate the molecular pathology and mutational mechanisms associated with these potentially pathogenic ZNF469 alleles. ZNF469 is a 3925 amino acid evolutionarily poorly conserved C2H2 zinc finger (C2H2-ZNF) protein of unknown function (30) . C2H2-ZNF genes constitute the largest class of transcription factors in humans making up 2% of all the human genes and represent the second largest gene family in humans (30) . The first identified members of the C2H2-ZNF family were Xenopus TFIIIA and Drosophila Kruppel, and thus genes of this family are often called ZNF genes of the TFIIIA or Kruppel type (30 -32) . Most C2H2-ZNF genes code for transcription factors which can bind DNA, RNA, DNA -RNA hybrids and proteins (32) . The physiological role of ZNF469 is not well established, but there is evidence that ZNF469 regulates extra-cellular matrix development and maintenance (15) . ZNF469 shows 30% sequence similarity to the helical parts of COL1A2 (MIM 120160), COL1A1 (MIM 120150) and COL4A1 (MIM 120130), all of which are highly expressed in the cornea (17) . The cornea is composed of 70% collagen, mostly collagen Type I, and there is evidence of a dysregulation of collagen homeostasis in the keratoconic cornea (33, 34) . Corneal thinning has been reported in osteogenesis imperfect (35) , which results from mutations in COL1A1 or COL1A2.
We have identified an enrichment of potentially pathogenic alleles in ZNF469 in patients with keratoconus. Further work is required to determine the functional impact of these variants, and the pathways regulated by ZNF469 which are involved in the development of keratoconus. Identifying genes responsible for keratoconus may also provide insights into the genetic basis for the normal variation in CCT. Decreased CCT has been proposed as a risk factor for primary open-angle glaucoma [POAG (MIM 137760)], the leading cause of irreversible blindness worldwide affecting .60 million people (36) . Individual patients with a thin cornea have a substantially increased risk for developing POAG (37, 38) , and glaucoma patients with a thin CCT have an increased severity and more rapid progression of visual field loss (39) . The genetic basis of CCT may provide insights into the development of glaucoma. Common SNPs near ZNF469 are the strongest CCT-associated loci, although the functional role of these SNPs is not known (10 -13) . The role ZNF469 plays in the development of POAG, and maintenance of CCT in normal subjects has not been determined. Combining resequencing with GWAS has yielded success in identifying rare disease-associated variants (40, 41) . Our study establishes the significant role ZNF469 plays in the development of keratoconus.
MATERIALS AND METHODS
All studies adhered to the tenets of the Declaration of Helsinki and were approved by the relevant institutions with all participants giving written informed consent.
Patients
Clinically affected keratoconus patients of European ethnicity were recruited as part of ongoing studies from Belfast (Belfast Health and Social Care Trust, UK), Leeds (St. James's University Hospital, Leeds, UK) and Lausanne (Jules-Gonin Eye Hospital, Lausanne and Institute for Research in Ophthalmology, Sion, Switzerland); and genomic DNA was extracted from peripheral blood leukocytes using commercial kits. The diagnosis of keratoconus was performed by an experienced ophthalmologist based on well-established clinical signs on slit-lamp biomicroscopy and cycloplegic retinoscopy; and a confirmatory videokeratographic map obtained using the Topographic Modelling System-1 (Computed Anatomy Inc., NY, USA), Orbscan II (Bausch & Lomb, Salt Lake City, UT, USA) or the Pentacam (Oculus, Wetzlar, Germany) (20, 27) . Slit-lamp biomicroscopy was used to identify the key features of keratoconus including stromal corneal thinning, Vogt's striae and Fleischer rings in affected individuals. The oil droplet sign and scissoring of the red reflex were assessed by retinoscopy performed with a fully dilated pupil. Patients were considered as having keratoconus if they had at least one clinical sign of the disease in conjunction with a confirmatory videokeratography map (20, 27 Table S4 ). Sequencing results were analysed manually using the sequence analysis software SeqScape 2.1.1 (Applied Biosystems, USA). Identified sequence variants were described according to the guidelines published by the Human Genome Variation Society. Variants were annotated in accordance with Ensembl transcript ENS T00000437464 or NCBI NM_001127464.1 (Build GRCh37/ hg19). The sequence variants were passed through a series of filtering steps shown in Figure 2 . If the sequence variants were present in the ethnically matched population-specific control data, they were excluded. The remaining sequence variants were required to have an MAF of ,0.1% in the data from dbSNP (Build 137), the May 2012 release of the 1KG Project and the EVS and NHLBI ESP. Following this, the remaining non-synonymous alleles were filtered using SIFT which can identify if an amino acid substitution influences protein function resulting in a phenotypic change; classified as damaging or tolerated (44) . SIFT can distinguish between functionally neutral and deleterious amino acid changes in mutagenesis studies and on human polymorphisms (45, 46) . There are alternative prediction tools that use a combination of methods based on sequence homology, protein structure information and physicochemical properties of amino acids for prediction (44) . Given that ZNF469 is a poorly characterized protein with no verified structural homologues, the SIFT algorithm was applied as SIFT computes a combined score derived from the distribution of amino acid residues observed at a given position in the sequence alignment and the estimated unobserved frequencies of amino acid distribution calculated from a Dirichlet mixture and does not rely on structural or physiochemical information (44) . The conservation of the affected amino acid across species was analysed using Homologene (http://www.ncbi.nlm.nih.gov/homologene/) and multiple sequence alignment with ClustalX (http://www.clustal.org/) visualized with GeneDoc software (http://www.nrbsc.org/gfx/ genedoc/).
The collapsing method (47) was used to compare the frequency of remaining potentially pathogenic alleles between case and control subjects with the level of significance set to P , 0.05. This method involves collapsing genotypes across variants and applying a univariate test which is powerful for analysing rare variants (47) . Specifically, each individual was assigned an indicator variable that takes the value one if the subject carries at least one potentially pathogenic variant and zero otherwise. Whether the proportions of individuals with index variable one differ significantly in cases and controls were tested using a Fisher exact test on the corresponding contingency table of indicator variable counts. The estimated OR, RR, 95% CI and Fisher's exact P-value were calculated using JavaStat (http://statpages.org/ctab2x2.html). 
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